<DOC>
	<DOCNO>NCT02009826</DOCNO>
	<brief_summary>Previous research suggest central nervous system inflammatory activity critically involved disease development progression schizophrenia , complex interplay inflammatory mechanism lead development brain abnormality medical symptom relate schizophrenia . However , mutual interaction different inflammatory pathway relation disease course sufficiently study . This study therefore aim explore interaction neuroinflammatory mechanisms patient schizophrenia ass whether inflammatory activity schizophrenia state-dependent occur mainly psychotic episode .</brief_summary>
	<brief_title>Psychosis-Associated Neuroinflammation Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>Be man woman 18 40 year age , inclusive . Have sign inform consent document indicate understand purpose procedure require study willing participate study . Be medically stable basis physical examination vital sign perform Screening . Be medically stable basis clinical laboratory test perform Screening . If result serum chemistry panel , hematology , urinalysis outside normal reference range , subject may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . Be willing able adhere prohibition restriction specify protocol . Schizophrenia subject : Fulfill DSMV criterion schizophrenia spectrum ( DSMV # 295.1295.6 , 295.9 , 298.9 ) Be admit hospital firstepisode psychosis acute relapse psychosis , define : total score ≥14 positive scale `` Positive Negative Syndrome Scale '' ( PANSS ) least score 5 1 item score 4 2 `` psychotic '' PANSS item P2 , P3 , P5 G9 Screening . Use nonsteroidal antiinflammatory drug , paracetamol , immunosuppressant immunostimulating drug within 21 day screen . Use systemic corticosteroid within 21 day screen . Has history drug alcohol dependence accord DSMV criterion , except nicotine caffeine , within 6 month screen . Has history ( comorbid ) somatization mood disorder accord DSMV criterion within 6 month screen . Has positive test result drug abuse alcohol screen test day . Female subject : pregnant breastfeeding Has history chronic acute physical illness associate abnormal immune change within 2 week study . Leukocytosis ( i.e. , white blood cell count ≤ 11 x109 /L ) screen test day . Serology positive hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , HIV antibodies screen . Has medical history autoimmune disorder chronic inflammatory disease . Has receive electroconvulsive therapy last 6 month . Is currently enrol study investigational study drug . Worsening first time occurrence significant suicidality Has donate blood within 3 month screen . Has condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement . Low affinity binder TSPO , determine rs6971 polymorphism genotyping Screening Use benzodiazepines 3x halflife prior PETscan Presence irremovable magnetic material body Has medical history organic brain disease Has medical history traumatic brain injury Has medical history allergic reaction substance tracer fluid . Unwillingness inability subject undergo PET and/or MRI scan ( example due claustrophobia lack cooperation ) Healthy volunteer : Personal history psychotic disorder Family history psychotic bipolar disorder firstdegree relative Family history autoimmune disorder firstdegree relative Schizophrenia patient : Calgary Depression Scale Schizophrenia ( CDSS ) score &gt; 6 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Neuroinflammation</keyword>
	<keyword>Microglial activation</keyword>
</DOC>